Skip to main content
. 2019 Aug 14;8(11):e1647760. doi: 10.1080/2162402X.2019.1647760

Figure 5.

Figure 5.

(a,c) Wild type (WT) immunocompetent C57BL/6 mice were inoculated subcutaneously (s.c.) with Annexin A1 deficient (AnxA1−/-) murine MCA205 fibrosarcoma (a) or TC-1 non small cell lung cancer cells (c), respectively. (b,d) Formyl peptide receptor 1 knock out (Fpr1−/-) mice were inoculated s.c. with WT murine MCA205 fibrosarcoma (b) or TC-1 cells (d), respectively. Tumor size was routinely assessed. When tumor became palpable, mice received intratumorally (i.t.) either recombinant calreticulin (rCALR) or doxorubicin (DOXO), alone or in combination or an equivalent volume of phosphate-buffered saline (PBS). From left to right: (1) average (±SEM) tumor growth curves from one representative experiment of two; (2) tumor size distribution at day 25 (MCA205 Anxa1−/-, (a)), day 24 (MCA205 WT, (b)), day 21 (TC-1 Anxa1−/-, (c)) or day 18 (TC-1 WT, (d)) of data shown in (1); (3) individual growth curves from mice injected with DOXO alone or combined with rCALR. ****p < 0.0001, as compared to PBS-treated tumors; $$$$p < 0.0001, as compared to DOXO-treated tumors; #p < 0.0001, as compared to rCALR-treated tumors.